Integrative analysis of T cell subset-specific ICOS expression and tumor HLA class I/II expression in lung adenocarcinoma: implications for their interaction and clinical outcome
Cancer Immunology, Immunotherapy · 2026
DOI: 10.1007/s00262-026-04327-w ↗Kurz gefasst
Fachartikel in der Zeitschrift Cancer Immunology, Immunotherapy, 2026. Verfasst von Hiroyuki Yamada und 11 weiteren Autor:innen. Beteiligte Einrichtung: Department of Cell Pathology, Graduate School of Medical Sciences, Kumamoto University, 1-1-1, Honjo, Chuo-Ku, Kumamoto, 860-8556, Japan. Hauptthemen laut MEDLINE: Inducible T-Cell Co-Stimulator Protein, Adenocarcinoma of Lung, Lung Neoplasms, Lymphocytes, Tumor-Infiltrating. Die Arbeit nennt 40 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: Ministry of Education, Culture, Sports, Science and Technology of Japan, Kumamoto University.
Abstract (Originalsprache)
Inducible T cell costimulator (ICOS) is a CD28-family costimulatory receptor with bidirectional therapeutic effects on antitumor immunity, and HLA-mediated tumor recognition is essential for effective T cell responses. However, their clinicopathological significance in lung adenocarcinoma (LUAD) is not fully understood. We investigated subset-specific pattern of ICOS expression and examined whether ICOS + tumor-infiltrating lymphocyte (TIL) density and tumor HLA expression provide immune context and prognostic information in LUAD. We examined 228 resected LUADs by immunohistochemistry. ICOS + TIL density and HLA class I and HLA-DR status were compared with the densities of CD8 + , CD3 + CD8 − , and FOXP3 + TILs and with postsurgical outcomes. Subset-specific ICOS expression was evaluated using multiplex pseudocolored immunohistochemistry in 10 representative cases selected from the ICOS + TIL-high group and validated using a publicly available single-cell RNA-seq dataset. ICOS + TIL density correlated with each T cell subset. Multiplex analysis showed the highest ICOS positivity among Tregs, followed by CD4 + non-Tregs and CD8 + TILs. Because CD4 + non-Tregs were numerically predominant, ICOS + CD4 + non-Tregs constituted the largest ICOS + fraction. Single-cell RNA-seq analysis corroborated these findings. ICOS + TIL density was significantly higher in HLA-DR-strong tumors, and tumor HLA class I and HLA-DR were associated with longer recurrence-free survival. ICOS had no overall prognostic impact; however, among HLA-DR-strong tumors, ICOS-high patients tended toward longer cancer-specific survival. In LUAD, ICOS + TIL density largely reflects ICOS + CD4 + non-Treg infiltration and is enriched in HLA-DR-strong tumors. Tumor HLA expression was associated with favorable prognosis, and ICOS may have context-dependent clinical significance that warrants further investigation.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Cell Pathology, Graduate School of Medical Sciences, Kumamoto University, 1-1-1, Honjo, Chuo-Ku, Kumamoto, 860-8556, Japan.
- Department of Thoracic Surgery and Breast Surgery, Graduate School of Medical Sciences, Kumamoto University, 1-1-1, Honjo, Chuo-Ku, Kumamoto, 860-8556, Japan.
- Department of Cell Pathology, Graduate School of Medical Sciences, Kumamoto University, 1-1-1, Honjo, Chuo-Ku, Kumamoto, 860-8556, Japan. ycomo@kumamoto-u.ac.jp.
- Center for Metabolic Regulation of Healthy Aging, Kumamoto University, 1-1-1, Honjo, Chuo-Ku, Kumamoto, 860-8556, Japan. ycomo@kumamoto-u.ac.jp.
- Department of Tumor Pathology, Graduate School of Health Sciences, Kumamoto University, 4-24-1 Kuhonji, Chuo-Ku, Kumamoto, 862-0976, Japan.
- Division of Clinical Immunology and Cancer Immunotherapy, Center for Cancer Immunotherapy and Immunobiology, Graduate School of Medicine, Kyoto University, Yoshida-Konoe-Cho, Sakyo-Ku, Kyoto, 606-8501, Japan.
Förderung
- Ministry of Education, Culture, Sports, Science and Technology of Japan
- Kumamoto University
Zitieren
APA
Yamada, H., Yamada, R., Komohara, Y., Pan, C., Yoshii, D., Yano, H., Matsubara, E., Shinchi, Y., Tsukamoto, H., Fujiwara, Y., Ikeda, K., & Suzuki, M. (2026). Integrative analysis of T cell subset-specific ICOS expression and tumor HLA class I/II expression in lung adenocarcinoma: implications for their interaction and clinical outcome. Cancer Immunology, Immunotherapy. https://doi.org/10.1007/s00262-026-04327-w
Vancouver
Yamada H, Yamada R, Komohara Y, Pan C, Yoshii D, Yano H, et al. Integrative analysis of T cell subset-specific ICOS expression and tumor HLA class I/II expression in lung adenocarcinoma: implications for their interaction and clinical outcome. Cancer Immunology, Immunotherapy. 2026. doi:10.1007/s00262-026-04327-w
BibTeX
@article{Yamada2026,
author = {Yamada, Hiroyuki and Yamada, Rin and Komohara, Yoshihiro and Pan, Cheng and Yoshii, Daiki and Yano, Hiromu and Matsubara, Eri and Shinchi, Yusuke and Tsukamoto, Hirotake and Fujiwara, Yukio and Ikeda, Koei and Suzuki, Makoto},
title = {Integrative analysis of T cell subset-specific ICOS expression and tumor HLA class I/II expression in lung adenocarcinoma: implications for their interaction and clinical outcome},
journal = {Cancer Immunology, Immunotherapy},
year = {2026},
doi = {10.1007/s00262-026-04327-w}
}
EUVIMED